(Q43845678)

27 November 2017

title

Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment (English)

1 reference

27 November 2017

main subject

cervix uterine cancer

1 reference

9

Elisabeth G E de Vries

1 reference

27 November 2017

Elisabeth Pras

1

1 reference

27 November 2017

Pax H B Willemse

2

1 reference

27 November 2017

Alof A Canrinus

3

1 reference

27 November 2017

Henk W A de Bruijn

4

1 reference

27 November 2017

Wim J Sluiter

5

1 reference

27 November 2017

Klaske A ten Hoor

6

1 reference

27 November 2017

Jan G Aalders

7

1 reference

27 November 2017

Ben G Szabo

8

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

International Journal of Radiation Oncology Biology Physics

27 November 2017

published in

1 reference

27 November 2017

volume

52

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

23-32

1 reference

Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

If and when? The role of chemotherapy in locally advanced carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group stud

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Tumor-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Serial determinations and tissue localization

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Cervical carcinoma: a comparison of four potential biochemical tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Squamous cell carcinoma (SCC) antigen in patients with invasive cervical carcinoma during primary irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Serum level of squamous cell carcinoma antigen and tumor size are useful to identify preoperatively patients at high risk of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Concurrent chemo- and radiotherapy in patients with locally advanced carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Squamous-cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Correlation of squamous cell carcinoma antigen levels and treatment response in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Value of squamous cell carcinoma antigen levels in invasive cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Use of serum squamous cell carcinoma antigen assays in chemotherapy treatment of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Relationship between squamous cell carcinoma antigen levels and tumor volumes in patients with cervical carcinomas undergoing neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

Squamous cell carcinoma antigen in serum for monitoring of head and neck and uterine cervical squamous cell carcinomas after radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2801%2901805-3

7 January 2021

10.1016/S0360-3016(01)01805-3

Identifiers

DOI

1 reference

27 November 2017

1 reference